P
Philippe R. Bauer
Researcher at Mayo Clinic
Publications - 132
Citations - 4252
Philippe R. Bauer is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Medicine & Intensive care unit. The author has an hindex of 26, co-authored 116 publications receiving 3052 citations. Previous affiliations of Philippe R. Bauer include LSU Health Sciences Center Shreveport & Louisiana State University.
Papers
More filters
Journal ArticleDOI
Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study
Giacomo Bellani,John G. Laffey,Tài Pham,Fabiana Madotto,Eddy Fan,Laurent Brochard,Andrés Esteban,Luciano Gattinoni,Vesna Bumbasirevic,Lise Piquilloud,Lise Piquilloud,Frank van Haren,Frank van Haren,Anders Larsson,Daniel F. McAuley,Philippe R. Bauer,Yaseen M. Arabi,Marco Ranieri,Massimo Antonelli,Gordon D. Rubenfeld,B. Taylor Thompson,Hermann Wrigge,Arthur S. Slutsky,Antonio Pesenti,Antonio Pesenti +24 more
TL;DR: NIV was used in 15% of patients with ARDS, irrespective of severity category, and NIV seems to be associated with higher ICU mortality in patients with a PaO2/FiO2 lower than 150 mm Hg.
Journal ArticleDOI
Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study.
Bruno Levy,Pierre-Edouard Bollaert,C. Charpentier,Lionel Nace,Gérard Audibert,Philippe R. Bauer,P. Nabet,Alain Larcan +7 more
TL;DR: The metabolic and splanchnic effects of the combination of norepinephrine and dobutamine in hyperdynamic dopamine-resistant septic shock appeared to be more predictable and more appropriate to the current goals of septicshock therapy than those of epinephrine alone.
Journal ArticleDOI
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
Michael J. Joyner,Rickey E. Carter,Jonathon W. Senefeld,Stephen A. Klassen,John Mills,Patrick W. Johnson,Elitza S. Theel,Chad C. Wiggins,Katelyn A. Bruno,Allan M. Klompas,Elizabeth R. Lesser,Katie L. Kunze,Matthew A. Sexton,Juan C. Diaz Soto,Sarah E. Baker,John R. A. Shepherd,Noud van Helmond,Nicole C. Verdun,Peter W. Marks,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Robert F. Rea,David O. Hodge,Vitaly Herasevich,Emily R. Whelan,Andrew J. Clayburn,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew R. Buras,Matthew N.P. Vogt,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Nigel Paneth,De Lisa Fairweather,R. Scott Wright,Arturo Casadevall +39 more
TL;DR: In this paper, the anti-SARS-CoV-2 antibody levels in convalescent plasma used to treat hospitalized adults with Covid-19 were determined based on a U.S. national registry, and the primary outcome was death within 30 days after plasma transfusion.
Journal ArticleDOI
Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients.
Michael J. Joyner,Katelyn A. Bruno,Stephen A. Klassen,Katie L. Kunze,Patrick W. Johnson,Elizabeth R. Lesser,Chad C. Wiggins,Jonathon W. Senefeld,Allan M. Klompas,David O. Hodge,John R. A. Shepherd,Robert F. Rea,Emily R. Whelan,Andrew J. Clayburn,Matthew R. Spiegel,Sarah E. Baker,Kathryn F. Larson,Juan G. Ripoll,Kylie J. Andersen,Matthew R. Buras,Matthew N.P. Vogt,Vitaly Herasevich,Joshua J. Dennis,Riley J. Regimbal,Philippe R. Bauer,Janis E. Blair,Camille M. van Buskirk,Jeffrey L. Winters,James R. Stubbs,Noud van Helmond,Brian P. Butterfield,Matthew A. Sexton,Juan C. Diaz Soto,Nigel Paneth,Nicole C. Verdun,Peter W. Marks,Arturo Casadevall,De Lisa Fairweather,Rickey E. Carter,R. Scott Wright +39 more
TL;DR: New data provide robust evidence that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of CO VID-19 is more likely to reduce mortality.
Journal ArticleDOI
Acute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study
Elie Azoulay,Peter Pickkers,Marcio Soares,Anders Perner,Jordi Rello,Philippe R. Bauer,Andry Van de Louw,Pleun Hemelaar,Virginie Lemiale,Fabio Silvio Taccone,Ignacio Martin Loeches,Tine Sylvest Meyhoff,Jorge I. F. Salluh,Peter Schellongowski,Katerina Rusinova,Nicolas Terzi,Sangeeta Mehta,Massimo Antonelli,Achille Kouatchet,Andreas Barratt-Due,Miia Valkonen,Precious Pearl Landburg,Fabrice Bruneel,Ramin Brandt Bukan,Frédéric Pène,Victoria Metaxa,Anne Sophie Moreau,Virginie Souppart,Gastón Burghi,Christophe Girault,Ulysses V. A. Silva,Luca Montini,François Barbier,Lene B. Nielsen,Benjamin Gaborit,Djamel Mokart,Sylvie Chevret,Efraim investigators +37 more
TL;DR: HFNC has an effect on intubation but not on mortality rates; however, IMV was associated with mortality, the odds ratio depending on IMV conditions: NIV + HFNC failure (2.31, 1.09–4.91), first-line IMV (1.94–3.29), NIV failure (3.05–6.53), standard oxygen failure (4.27–9.38).